Alex Carchidi, expert in dissecting the biotech sector, discusses the importance of diversification and the challenges faced in the industry. Topics include gene editing, gene therapy, the impact of high drug prices, and the risks and rewards of investing in biotechs. Attention is also given to the future of the US healthcare system and the focus on treating rather than curing diseases in the pharmaceutical industry.
Diversification is crucial when investing in the risky biotech sector to minimize potential losses.
Close attention to news cycles, clinical trial data, and regulatory updates is essential for identifying positive and negative catalysts in the biotech industry.
Deep dives
Biotech Background and Interest
The speaker shares their background in the biotech field, including working in an academic research laboratory and at biotech startups. They express a keen interest in science-based solutions for improving human health.
Investing in Biotech Companies
The speaker advises approaching biotech companies as highly risky and speculative investments, recommending diversification to mitigate potential losses. They highlight the importance of not relying on one company to find a breakthrough therapy, but rather investing in multiple companies targeting the same disease.
Emerging Trends in Biotech
The speaker discusses the current landscape of biotech, highlighting the challenges in funding and the underperformance of publicly listed biotech companies. However, they emphasize that significant research and development activities are occurring, particularly in the areas of gene editing, gene therapy, and therapies for type 2 diabetes and obesity.
Future Outlook and Strategies
The speaker anticipates increased consolidation in the biotech industry and expects more activity in the next couple of years. They stress the importance of closely following news cycles, clinical trial data, and regulatory updates to identify positive and negative catalysts. Additionally, they mention the pricing challenges and the need for realistic pricing strategies to ensure access and adoption of new medicines.
Alex Carchidi dissects the biotech sector - mostly highly risky, borderline investments. Diversification pays off (3:40). Funding is hard to come by and performance has not been great but ebb will give way to flow (6:00). Biotech and pharma; gene editing, gene therapy competitive story (7:45). Buy the rumor, sell the news is cliched but true for these stocks (17:00). Getting realistic about high price of drugs (20:05).
For full access to analyst ratings, stock quant scores as well as dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode